Indeed, studies have documented that targeting M2 markers (e.g. IL‐4 and/or IL‐13) can reduce primary breast tumor burden and prevent breast cancer metastasis (Little et al., 2019; Papageorgis et al., 2015; Park et al., 2017; Venmar et al., 2014). Here, IL13 is linked to breast neoplasm.